Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of pre-transplant diffusion lung capacity for nitric oxide (DLNO) and of DLNO/pre-transplant diffusion lung capacity for carbon monoxide (DLNO/DLCO) ratio on pulmonary outcomes in adults receiving allogeneic stem cell transplantation for hematological diseases.
Le Bourgeois A, Malard F, Chevallier P, Urbistandoy G, Guillaume T, Delaunay J, Peterlin P, Lemarchand P, Germaud P, Mohty M, Moreau P, Chambellan A. Le Bourgeois A, et al. Among authors: guillaume t. Bone Marrow Transplant. 2016 Apr;51(4):589-92. doi: 10.1038/bmt.2015.284. Epub 2015 Nov 23. Bone Marrow Transplant. 2016. PMID: 26595083 Free article. Clinical Trial. No abstract available.
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Roland V, Mahé B, Juge-Morineau N, Dubruille V, Guillaume T, Vigouroux S, Moreau P, Milpied N, Garand R, Avet-Loiseau H, Harousseau JL. Chevallier P, et al. Among authors: guillaume t. Leuk Res. 2005 Sep;29(9):1003-7. doi: 10.1016/j.leukres.2005.02.005. Epub 2005 Apr 8. Leuk Res. 2005. PMID: 16038726
Surgical treatment of a foscavir-resistant atypical Cytomegalovirus pneumonia in an allogeneic stem cell transplant recipient.
Bressollette-Bodin C, Claver A, Boutolleau D, Chevallier P, Guillaume T, Gastinne T, Moreau P, Harousseau JL, Imbert-Marcille BM, Le Gouill S. Bressollette-Bodin C, et al. Among authors: guillaume t. Haematologica. 2008 May;93(5):e39-41. doi: 10.3324/haematol.12199. Haematologica. 2008. PMID: 18450727 Free article. No abstract available.
Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens.
Cahu X, Mohty M, Faucher C, Chevalier P, Vey N, El-Cheikh J, Guillaume T, Furst S, Delaunay J, Ayari S, Moreau P, Gastaut JA, Harousseau JL, Blaise D. Cahu X, et al. Among authors: guillaume t. Bone Marrow Transplant. 2008 Nov;42(10):689-91. doi: 10.1038/bmt.2008.231. Epub 2008 Aug 4. Bone Marrow Transplant. 2008. PMID: 18679370 No abstract available.
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau JL. Chevallier P, et al. Among authors: guillaume t. J Clin Oncol. 2008 Nov 10;26(32):5192-7. doi: 10.1200/JCO.2007.15.9764. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854573 Clinical Trial.
Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases.
Chevallier P, Robillard N, Houille G, Ayari S, Guillaume T, Delaunay J, Harousseau JL, Avet-Loiseau H, Mohty M, Garand R. Chevallier P, et al. Among authors: guillaume t. Leukemia. 2009 Apr;23(4):806-7. doi: 10.1038/leu.2008.303. Epub 2008 Oct 30. Leukemia. 2009. PMID: 18971949 No abstract available.
Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors.
Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Flandrois G, Devys A, Stocco V, Cesbron A, Dehaut F, Moreau P, Harousseau JL, Mohty M. Brissot E, et al. Among authors: guillaume t. Bone Marrow Transplant. 2009 Nov;44(9):613-5. doi: 10.1038/bmt.2009.60. Epub 2009 Mar 23. Bone Marrow Transplant. 2009. PMID: 19308036 No abstract available.
Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors.
Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Moreau P, Harousseau JL, Mohty M. Brissot E, et al. Among authors: guillaume t. Bone Marrow Transplant. 2010 Apr;45(4):786-8. doi: 10.1038/bmt.2009.218. Epub 2009 Aug 31. Bone Marrow Transplant. 2010. PMID: 19718059 No abstract available.
247 results